Pα+ subscriber content: On Monday, the inaugural meeting of the MEP Action Group for the Medical Use of Psychedelics took place at the European Parliament in Brussels. We share key takeaways and discussion points.
On Monday, the inaugural meeting of the MEP Action Group for the Medical Use of Psychedelics took place at the European Parliament in Brussels. We share key takeaways and discussion points.
Notes from the Conference Call: Cybin’s Deuterated Psilocybin Analog Results • Federal Appeals Court Throws Lifeline to Psilocybin Rescheduling Effort • UK Report on Barriers to Research with Controlled Drugs Expected to Publish Soon • Meta Ignores its Oversight Board’s Suggestions Regarding Ketamine Ads • ‘Mushroom Pilot’ Case Sparks Soul-Searching • Leading UK Psychedelic Drug Policy Reform Group Rebrands, Founder Mired by Arrest • NIH to Establish and Fund a National Cannabis Research Centre • New NIDA Grant Opportunity for Psychedelics • Ethics Approval for Study of Psychedelics in Romantic Relationships • Other Headlines & Weekend Reads.
Psychedelic Alpha is launching a reader-supported model to support our coverage of the space. It’s called Pα+ and you can benefit from an introductory offer today.
Today, Cybin shared topline, interim data from a Phase 2 study of its deuterated DMT candidate (CYB003) in major depressive disorder (MDD). We share a quick reaction including comments from Cybin CEO, Doug Drysdale.